WO1997039744A1 - Forme galenique solide de cisapride independante du ph a liberation immediate - Google Patents

Forme galenique solide de cisapride independante du ph a liberation immediate Download PDF

Info

Publication number
WO1997039744A1
WO1997039744A1 PCT/EP1997/001462 EP9701462W WO9739744A1 WO 1997039744 A1 WO1997039744 A1 WO 1997039744A1 EP 9701462 W EP9701462 W EP 9701462W WO 9739744 A1 WO9739744 A1 WO 9739744A1
Authority
WO
WIPO (PCT)
Prior art keywords
cisapride
dosage form
tartrate
tablet
oral dosage
Prior art date
Application number
PCT/EP1997/001462
Other languages
English (en)
Inventor
Paul Marie Victor Gilis
Guido Franciscus Smans
Guido Jozef Maria Gijs
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU22904/97A priority Critical patent/AU720582B2/en
Priority to NZ331705A priority patent/NZ331705A/xx
Priority to JP9537646A priority patent/JPH10510559A/ja
Priority to SK1446-98A priority patent/SK144698A3/sk
Priority to EA199800861A priority patent/EA000804B1/ru
Priority to EE9800269A priority patent/EE03552B1/xx
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Priority to BR9708585A priority patent/BR9708585A/pt
Priority to PL97328917A priority patent/PL328917A1/xx
Priority to IL12597997A priority patent/IL125979A0/xx
Publication of WO1997039744A1 publication Critical patent/WO1997039744A1/fr
Priority to NO984016A priority patent/NO984016L/no
Priority to BG102812A priority patent/BG102812A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention concerns solid dosage forms of particular salts of cisapride, more particularly c ⁇ sap ⁇ de-(L)-tartrate, c ⁇ sap ⁇ de-(D)-tartrate, cisapride-sulfate, or cisapride citrate, which avoid drugfood interaction and which allow co-medication of agents that increase the pH of the stomach.
  • the invention particularly relates to solid oral dosage forms suitable for rapid disintegration and dissolution.
  • the present invention also concerns tablets which can be prepared via direct compression.
  • the abso ⁇ tion and bioavailability of any particular therapeutic agent can be affected by numerous factors when dosed orally.
  • factors include the presence of food in the gastrointestinal (GI) tract because, in general, the gastric residence time of a drug is usually significantly longer in the presence of food than in the fasted state.
  • the bioavailability of a drug is affected beyond a certain point due to the presence of food in the GI tract, the drug is said to exhibit a "food effect" or show a drugfood interaction.
  • the risk involved with taking drugs exhibiting a food-effect derives from the fact that absorption into the bloodstream may be adversely affected by not taking the drug on the correct point in time so that the patient risks insufficient absorption to remedy the condition for which the drug was administered.
  • Cisapride has the following structural formula :
  • Cisapride is a racemic mixture of two enantiomers.
  • Cisapride has excellent gastrointestinal motiht ⁇ stimulating properties and is reported to be devoid of antidopaminergic activity Its utility in a variety of gastro-intestinal disorders has already been reported extensively It is currently being marketed as a medicine to treat gastro-oesophageal reflux disorders, inter alia oesophagitis, gastroparesis, negative upper digestive discomfort and intestinal pseudo-obstruction.
  • Cisapride monohydrate is currently commercially available as tablets, suspension and granules under registered tradenames, such as PREPULSID rM , PROPULSIDTM, PROPULSIN I M , ACENALINTM, ALIMIX 1 M (this list is not comprehensive).
  • Cisapride in its monohydrate form has a pH-dependent solubility and dissolution profile. Hence the bioavailability of cisapride or cisapride monohydrate is pH dependent. Cisapride monohydrate has a low solubility and low dissolution when present in a neutral or basic environment Therefore, the information leaflet of cisapride monohydrate mentions that the drug should be taken 15 to 30 minutes before meals. The rationale being that the solid dosage form comprising cisapride monohydrate arrives in a more or less empty stomach, where the pH is reasonably low and hence the cisapride can dissolve.
  • cisapride monohydrate shows a food effect, which can be expressed as the ratio between the AUC in fed state over AUC in fasted state.
  • AUC is the abbreviation of Area Under the Curve, which is an indication of the amount of active ingredient that is present in the blood.
  • the 1 atio for cisapride monohydrate of AUC in fed state over AUC in fasted state is about 1 35 (p > 0.01 )
  • a drug showing no food effect would have a ratio of 1 (in an ideal case)
  • a patient taking cisapride monohydrate has to follow the above described regimen quite strictly in order to create the optimum conditions for high bioavailability of cisapride monohydrate and consequently to maximise the benefit from the drug taken.
  • Patients do not always have the necessary discipline to take their medication at the optimum point in time. Consequent! ⁇ a dosage torm that would make the bioavailability independent of the meal (or Irom any other event for that matter) would mean a serious improvement over the p ⁇ or art oral dosage forms of cisapride monohydrate and reduce the extent of variability in absorption between patients.
  • Cisapride monohydrate is prescribed for infants (children up to 1 year).
  • the fact that cisapride monohydrate has to be administered up to 30 minutes before the meal implies that parents often have to wake said children up, administer the cisapride monohydrate and then wait half an hour to feed said children.
  • Said procedure is very unpractical and it would be very interesting to find a form of cisapride which is suitable for administering to infants just before the meal or even after the meal or better still, completely independent of when the meal is taken.
  • cisapride is used to treat people having stomach or esophagus problems. Often, these patients receive co-medication to increase the pH of the stomach.
  • co-medication are antacids, such as aluminum containing antacids, e.g. Al(OH)3, calcium containing antacids, e.g. CaCO3, or magnesium containing antacids, e.g. Mg(OH)2; H2-antagonists. e.g. cimetidine, ranitidine, famotidine, nizatidine, roxatidine and the like; or proton pump inhibitors, e.g. omeprazole, lansoprazole, rabeprazole. At the moment the preferred comedication prescribes proton pump inhibitors.
  • WO 94/01 1 12 and WO 94/01 1 1 1 published on 20 January 1994, assigned to Sepracoi Ine, disclose very generally methods of using (-)-cisapride respectively (+)-cisapride as well as the therapeutically acceptable salts thereof for the treatment of gastro- esophageal reflux disease and other disorders.
  • said applications there is no specific mentioning of the use of the presently disclosed salts and the properties thereof.
  • EP 670160 published on 6 September 1995, assigned to Gergely, discloses a granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation.
  • a granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation.
  • cisapride effervescent tablets are described. Again, in this application only effervescent systems are disclosed which are totally different from the presently disclosed invention.
  • WO 95/01803 published on January 19, 1995 discloses combinations of H2 antagonists and gastrointestinal motility agents. Said patent application specifically mentions the use of cisapride in said combination.
  • the disadvantage of said prior art combination is that antacids, H2-antagon ⁇ sts and especially proton pump inhibitors can cause a considerable raise in the pH in the stomach. With antacids the pH of the stomach, which is normally between 1 and 1.5, can raise to about 4 5 and with proton pump inhibitors the pH of the stomach can raise to about 6.5. In such an environment cisapride monohydrate does not dissolve quickly enough to give fast appropriate relief.
  • the (3R4S) and (3S4R) refer to the respective enantiomers of cisapride and the (2R3R) refers to the optically pure L-tartrate. It was also shown that formulations containing c ⁇ sapr ⁇ de-(L)-tartrate released cisapride in a racemic form, i.e.
  • the solid dosage forms comprising a salt of cisapride with an acid selected from sulfuric acid, (L)-tarta ⁇ c acid, (D)-tarta ⁇ c acid or citric acid, preferably c ⁇ sap ⁇ de-(L)-tartrate suitable for rapid dissolution
  • the formulations are preferably suitable for rapid disintegration as well as dissolution
  • the preferred formulations are oral solid dosage forms
  • suitable for rapid dissolution refers to the fact that from the solid dosage forms of the present invention the active ingredient can dissolve for more than 60 % within 1 hour in a pH range from 1 to 7 Said dissolution can be measured according to standard methods described in the European Pharmacoeipea or as set forth in USP test ⁇ 71 1> in a USP-2 dissolution apparatus. This latter test is described in US Pharmacopeia XXII, pp 1578-1579
  • salts of cisapride have a better dissolution in artificial gastric juice than others • those salts are the (L)-tartrate, (D)-tartrate, the sulfate and the citrate. Moreover, said salts of cisapride show a dissolution profile which is substantially pH independent It should be noted that the salt form of cisapride with hydrochloric acid as well as with maleic acid dissolve slower than the cisapnde monohydrate itself
  • solid oral dosage forms generally refers to tablets (both swallowable-only and chewable forms) and capsules
  • present composition of salt forms of cisapnde may be formulated into tablets, caplets, gelcaps oi capsules
  • This invention encompasses formulations comprising the salts of cisapride according to the present invention and further comprising a substance which can influence the acidity of the stomach
  • Said substance can be any medication that inci eases the pH of the stomach (in other words • renders the stomach more basic)
  • examples of just medication that increases the pH of the stomach should be mentioned antacids.
  • Thc invention also relates to products containing any ol the salt forms of cisapnde of the present invention, preferably c ⁇ sap ⁇ de-(L)-tartrate, and an antacid or an H2- antagonist or especially a proton pump inhibitor as a combined preparation for simultaneous, separate or sequential use in treating gastrointestinal disorders, especially gastro-esophageal reflux related conditions
  • compositions of the present invention may optionally include an anti-flatulent, such as simethicone, alpha-D-galactosidase and the like
  • Said products comprising combinations of antacids, H2 antagonists or proton pump inhibitors on the one hand and the cisapnde salt forms on the other hand, optionally further combined with an anti flatulent provide the dual action approach to the treatment of gastrointestinal disorders as described in WO 95/01803, l e the salt of cisapnde as gastrointestinal motility agent offers an enhanced motility while the antacid, the H2-antagon ⁇ st or the proton pump inhibitor offers a systemic effect of reduced acid production
  • the present invention therefore further provides a method of preventing, treating and relieving heartburn, indigestion, sour stomach, overindulgence, gastro esophageal reflux, constipation, dyspepsia and other gastrointestinal disorders, and gastrointestinal disorders, and optionally flatulence, in mammals, including humans, in need of treatment thereof, comprising administering lo such organism (i) an therapeutically effective amount ot an antacid, an H2 antagonist or a proton pump inhibitor, and (n) a therapeutically effective amount of a salt form of cisapnde of the present invention, and optionally (in) a therapeutically effective amount of an anti-flatulent, in particular simethicone or alpha-D-galactosidase (ADG)
  • ADG alpha-D-galactosidase
  • H2 antagonists such as famotidine, ranitidine and cimetidine are also commercially available under different Tradenames
  • Pioton pump inhibitors such as, omeprazole, lansoprazole, rabeprazole and the like are eithei commercially available or known in the art
  • Simethicone is a well-known and commercially available anti flatulent Alpha- D-galactosidase
  • ADG is a commercially available enzyme preparation used to hydroly/e indigestible sugars found in beans or bean pioducts
  • the active ingredients, othei than the salts of cisapnde are theietoie leadily commercially available
  • the dosages of each of the active ingredients may vary depending upon the severity of the condition and the particular biochemistry and need of the patient.
  • the dosages of the active ingredients may also vary depending upon whether the active ingredients are administered in tablet or liquid form or via some other suitable delivery method.
  • a physician or clinician may readily
  • the tablets or capsules according to the invention comprise the salt forms of cisapride, preferably cisapride-(L)-tartrate, which are preferably in a microfine or micronized form for some uses.
  • Micronized forms of the salt forms of cisapride, especially cisapride-(L)-tartrate may be prepared by micronization techniques known in the art, e.g. by milling in appropriate mills and sieving through appropriate sieves.
  • the specific surface area of said micronized material should at least amount to about 10 x 10 ⁇ cm ⁇ /g (1 x 10 ⁇ nrVkg), preferably the specific surface area should amount to more than 12 x 10 ⁇ cm ⁇ /g (1.2 x 10 m ⁇ /kg), most preferably the specific area should amount to more than 14 x 10 3 cm ⁇ /g (1.4 x 10 ⁇ m ⁇ /kg).
  • the characteristics of the micronized salt forms of cisapride, especially cisapride-(L)-tartrate, expressed in a different way are as follows. At most 50% of the particles may have a diameter larger than 24 ⁇ m (i.e. 24 x 10" 0" m), hence the dl 50 has a maximum value of 24 ⁇ m (dl stands for diameter measured via laser diffraction).
  • a more interesting range is from about 20 ⁇ m to 100 ⁇ m.
  • the preferred dl 50 is about 24 ⁇ m.
  • the preferred dl 50 is about 50 ⁇ m.
  • the solid oral dosage form when in a unit dose form comprises the equivalent of about 0.1 mg to 100 mg of cisapride in it's base form, more particularly are envisaged dosage forms which contain the equivalent of about 5 mg, about 10 mg, and about 20 mg of cisapride in it's base form.
  • the excipients of the oral dosage forms of the present invention should be chosen to allow a fast dissolution of the active ingredients.
  • Two solid oral dosage forms are preferred, i.e. tablets and capsules.
  • excipients Especially with tablets, the choice of excipients is important.
  • the excipients should allow a fast dissolution and on the other hand the excipients should allow a convenient industrial production of tablets with an appropriate aspect, an appropriate friability and sufficient hardness.
  • Tablets should have an appropriate hardness and friability mainly because said tablets need to be manufactured on an industrial scale at presses with high speed and said tablets have to be packed or filled of in all kinds of containers. If the tablet has an insufficient hardness or is rather friable the tablet that is taken by the patient may be broken or parts of the tablet may have crumbled into powder. As a consequence of this insufficient hardness or friability the patient can no longer be certain that he is taking in the correct amount.
  • the minimum required hardness of the tablets should be from about 1.5 daN (deca Newton) as measured by the test as described in the European Pharmacopoeia (3 th Edition, 1997) on page 135, "resistance to crushing of tablets”. It should be noted that hardness, amongst other properties, of tablets is dependent upon the shape of the tablets.
  • Tablets may be circular or oblate or oblong or any other shape that is known in the art.
  • the tablets may be scored. It should be noted that also the shape of the tablets may for instance have an influence the disintegration rate.
  • the disintegration of tablets is measured according to the pharmaceutical technical procedure as described in the European Pharmacopoeia, third edition, (1997), page 127.
  • the disintegration time of the present tablets should be less than about 30 minutes, interestingly less than 20 minutes and more interestingly less than about 15 minutes.
  • the preferred tablets even have a disintegration time of less than about 3 minutes, even less than about 1.5 minutes.
  • the tablets of the present invention comprise tablet disintegrants, such as starch, pregelatinised starch, sodium starch glycolate (Explotab®), crosslinked povidone, crosslinked sodium carboxymethylcellulose, clays, microcrystalline cellulose (of the type available under the registered Trademark Avicel®), alginates, gums and others known in the art.
  • tablet disintegrants such as starch, pregelatinised starch, sodium starch glycolate (Explotab®), crosslinked povidone, crosslinked sodium carboxymethylcellulose, clays, microcrystalline cellulose (of the type available under the registered Trademark Avicel®), alginates, gums and others known in the art.
  • Tablets of the present invention preferably comprise as disintegrant crosslinked Carmellose Sodium (Carmellose Sodium is the British Approved Name of sodium carboxymethylcellulose, i.e. the sodium salt of a ether of cellulose, see Martindale , the Extra Pharmacopeia, 29 th edition, page 1433). Said crosslinked Carmellose Sodium is referred to as Croscarmellose Sodium (USP NF, 1995 Edition, page 2238)
  • the disintegrant may be present in an amount of about 2 % (w/w) to about 15 % (w/w).
  • An interesting range for the disintegrant is from about 3 % (w/w) to about 10 % (w/w). When percentages are used, these percentages are weight per weight (w/w) and represent the ratio (in percent) of the ingredient or the excipient based on the total weight of the tablet (or in the case of coated tablets of the tablet core).
  • the “tablet core” is the tablet without the coating.
  • the tablet may further be formulated to include a variety of conventional excipients, depending on the exact formulation, such as binders, flavorings, buffers, diluents, colors, lubricants, sweetening agents, and glidants. Some excipients can serve multiple pu ⁇ oses.
  • flavors may be inco ⁇ orated in the composition, which may be chosen from synthetic flavor oils and flavoring aromatics and/or natural oils, extracts from plant leaves, flowers, fruits and so forth and combinations thereof. These may include cinnamon oil, oil of wintergreen, peppermint oils, bay oil, anise oil, eucalyptus, thyme oil. Also useful as flavors are vanilla, citrus oil, including lemon , orange, grape, lime and grapefruit, and fruit essences, including apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so fort. The amount of flavor may depend on a number of factors including the organoleptic effect desired. Generally the flavor will be present in an amount from about 0.5 % (w/w) to about 3.0 % (w/w), when a flavor is used.
  • a variety of materials may be used as fillers or diluents. Examples are spray-dried or anhydrous lactose, sucrose, dextrose, mannitol, sorbitol, starch, cellulose (e.g. micro- crystalline cellulose; Avicel), dihydrated or anhydrous dibasic calcium phosphate, and others known in the art.
  • a tablet can comprise one single filler or diluent or a mixture of fillers or diluents. For instance, a mixture of lactose and micro crystalline cellulose can be used. Lactose is used as a pure diluent, while microcrystalline cellulose is a filler that has the property of yielding tablets with an appropriate hardness and it has disintegrant properties because cellulose fibers swell in contact with water.
  • lactose monohydrate DC which corresponds with Pharmatose DCL 1 1 that is commercially available from DMV International, The Netherlands, said lactose monohydrate DC is spray-dried lactose monohydrate.
  • Fillers or diluents may be present in a range from about 50 % (w/w) to about 95 % (w/w) based on the total weight of the tablet or tablet core. Interestingly the amount of fillers or diluents range from about 65 % (w/w) to about 90 % (w/w). Preferably, the amount of fillers or diluents range from about 66 % (w/w) to about 86 % (w/w). - -
  • a spray-dried mixture of lactose monohydrate and microcrystalline cellulose in a ratio of about 75 % by weight of lactose monohydrate and about 25 % by weight of microcrystalline cellulose can be used.
  • This mixture is commercially available under the registered tradename MICROCELAC®.
  • This spray-dried mixture of lactose monohydrate and microcrystalline cellulose has the advantage that it will promote ordered mixing, which improves the content uniformity of the tablets.
  • the solid oral dosage forms contain relatively small amounts of active ingredient in a large amount of filler. In such conditions content uniformity can pose problems, i.e. the tablets prepared in the same batch may not all have the same content of active ingredient due to segregation during manufacturing.
  • the spray-dried mixture of lactose monohydrate and microcrystalline cellulose has a porous structure wherein the active ingredient cisapride-(L)-tartrate can be inserted, leading to ordered mixing and consequently a good content uniformity.
  • Said MICROCELAC® is present in an amount ranging from about 80 % (w/w) to 95 % (w/w) based on the total weight of the tablet or the tablet core in the case of film coated tablets.
  • the MICROCELAC® is present in an amount of about 87 % (w/w).
  • Lubricants can also be employed in the manufacture of certain dosage forms, and will usually be employed when producing tablets.
  • examples of lubricants are magnesium stearate, stearic acid, sodium stearyl fumarate, magnesium lauryl sulfate, hydrogenated vegetable oil and others known in the art.
  • Preferred lubricants are magnesium stearate and sodium stearyl fumarate.
  • Lubricants generally are present in an amount ranging from about 0.2 % (w/w) to 7.0 % (w/w) based on the total weight of the tablet or the tablet core in the case of film-coated tablets. Moreover, lubricants are present in amounts ranging from about 0.5 % (w/w) to about 3.0 % (w/w). Preferably, lubricants are present in amounts ranging from about 0.9 % (w/w) to about 1.25 % (w/w).
  • Glidants are normally used in the manufacture of tablets and also capsules.
  • interesting glidants are calcium silicate, magnesium silicate, colloidal anhydrous silica or talc. Mixtures of glidants may also be used.
  • Preferred glidant for the tablet core or the capsule of this invention is colloidal anhydrous silica.
  • the type normally used is commercially available under the tradename Aerosil®.
  • Glidants are normally present - -
  • m an amount ranging from about 0.05 % (w/w) to about 1 % (w/w) based on the total weight of the tablet core content.
  • the preferred amount of glidant is about 0.3 %.
  • Binders may be acacia, alginic acid, carboxymethylcellulose (sodium), cellulose (microcrystalline), dextrin, ethylcellulose, gelatin, glucose (liquid), guar gum, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, polyethylene oxide, povidone, starch (pregelatinized) or syrup.
  • interesting binders are the hydroxypropyl methylcelluloses, especially the low-viscosity hydroxypropyl methylcelluloses.
  • Preferred binder is hydroxypropyl methylcellulose 2910 of which a 2 % aqueous solution at 20 °C has a viscosity of 15 mPa.s
  • Coloring agents and pigments include titanium dioxide and/or dyes approved for use in food and pharmaceuticals.
  • a coloring agent is an optional ingredient in the tablet of the present invention, but when used, the coloring agent will be present in an amount up to 3.5 % (w/w) based on the total tablet weight or the tablet core in the case of film-coated tablets.
  • the coloring agent is present in the coating of the tablet, where again the coloring agent may be present in an amount ranging from 0.01 % (w/w) to about 10 % (w/w) based upon the total weight of the coating, an interesting range starts from about 0.20 % (w/w) up to about 7.5 % (w/w) based upon the total weight of the coating.
  • tablet blends may be dry-granulated or wet-granulated before tabletting.
  • cisapride-(L)-tartrate it was possible to prepare tablets using direct compression techniques.
  • cisapride monohydrate would be used as an active ingredient the formulation requires a surfactant to obtain the necessary wettability of the cisapride monohydrate.
  • a wet-granulation step is required.
  • the tablets of the present invention can be prepared by direct compression, i.e. the "usual" wet-granulation step can be omitted This causes a considerable cost reduction in the production of these tablets.
  • Tablets of the present invention may be film-coated to provide ease of swallowing, taste masking and an elegant appearance. Many polymeric film-coating materials are known in the art.
  • Known film-coating agents are sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methyl cellulose phthalate, methacrylic acid copolymer, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, wax, zein.
  • a preferred film-coating material is hydroxypropyl methylcellulose (HPMC). HPMC may be obtained commercially.
  • Coating agents are normally present in an amount ranging from about 50 % (w/w) to about 95 % (w/w) based upon the total weight of the film coating.
  • the interesting range is from about 50 % (w/w) to about 65 % (w/w).
  • Antiadhesives are normally used in the film coating process to avoid sticking effects during film formation and drying.
  • the preferred antiadhesive for this pu ⁇ ose is talc.
  • the antiadhesive and especially talc is present in the film coating in an amount of about 5 % (w/w) to 15 % (w/w) based upon the total weight of the coating.
  • plasticizers such as castor oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, glycerin, polyethylene glycol, propylene glycol, triacetin, triethyl citrate. Also mixtures of plasticizers may be utilized.
  • the type of plasticizer depends upon the type of coating agent.
  • Preferred plasticizer according to the present invention is propylene glycol.
  • Said plasticizer is normally present in an amount ranging from 5 % (w/w) to 30 (w/w) based on total weight of the film coating.
  • interesting range of plasticizer is from about 12 % (w/w) to about 16 % (w/w) based on the total weight of the film coating.
  • Preferred amount of propylene glycol according to the present invention is about 14 % (w/w).
  • An opacifier like titianium dioxide may also be present in an amount ranging from about 10 % (w/w) to about 20 % (w/w) based on the total weight of the coating.
  • colouring agents and pigments may be present in the film coating.
  • Preferred colouring agents are ferric oxides, which can either be red, yellow, black or blends thereof.
  • Said film-coating process may be carried out utilizing spray-coating equipment well- known in the art.
  • the coating can be carried out in a perforated pan such as those manufactured under the tradename of Glatt® (for example Glatt Coater 750) AccelaCota® and HiCoater®.
  • the tabletting process itself is otherwise standard and readily practised by forming a tablet from a desired blend or mixture of ingredients into the appropriate shape using a conventional tablet press. Pressures are used ranging from about 0.5 ton/cm 2 (corresponding to about 50 MPa) to about 2.0 ton/cm 2 (corresponding to about 200 MPa). Below the lower limit, the tablets formed will not show appropriate hardness and above the higher limit the tablets may be so hard that they do not dissolve any more. Preferred range is from about 1.1 ton/cm 2 (corresponding to about 110 MPa) to about 1.7 ton/cm 2 (corresponding to about 170 MPa).
  • Capsules according to the present invention comprise, apart form the active ingredient, fillers, glidants, lubricants and disintegrants.
  • the same fillers, glidants and lubricants as described above for the tablets may be used in the capsules.
  • Preferred filler is lactose.
  • Preferred glidants are colloidal silicon dioxide and talc.
  • Talc also provides the anti-adherent properties needed to handle the powders.
  • Preferred lubricant is magnesium stearate.
  • Maize starch can be used as a disintegrant, which is a necessary ingredient for the capsule content in the case the capsule filling equipment uses tamping. In capsule filling equipment using tamping, the capsule content is packed together in several consecutive strokes and at the last stroke the packed capsule content is delivered into the capsule.
  • Fillers are present in an amount ranging from about 60 % (w/w) to about 90 % (w/w) based upon the total weight of the capsule content.
  • the fillers are present in an amount ranging from about 70 % (w/w) to about 80 % (w/w) based upon the total weight of the capsule content.
  • the fillers are present in an amount of about
  • Glidants are present in an amount of about 4% (w/w) to 7 % (w/w) based upon the total weight of the content of the capsule.
  • the glidants are present in an amount of about 6 % (w/w) based upon the total weight of the content of the capsule.
  • the lubricant or lubricants are present in an amount ranging from about 0.5 % (w/w) to about 2.0 % (w/w). Preferably, the lubricant or lubricants are present in an amount of about 1.25 % (w/w) based upon the total weight of the content of the capsule.
  • Capsules are normally prepared from gelatin, they may be soft or hard gelatin capsules.
  • the capsules are prepared in a conventional way.
  • the filler for instance lactose, is milled together with the active ingredient and sieved.
  • the resulting mixture is added to a mixture of the remainder of the excipients and mixed in a planetary mixer until a homogenous mixture is obtained.
  • This powder is filled off in the capsule using art- known (automatic) capsule filling equipment.
  • An advantage of the present solid oral dosage form is that, even when the solid oral dosage form according to the present invention has not yet completely dissolved in the acid environment of the stomach and is passed through to the gut, where the environment is about neutral, i.e. much less acidic, then still the cisapride tartrate is able to dissolve quickly, which is not the case with cisapride monohydrate.
  • the pharmaceutical dosage form is to be used as a medicine for treating gastrointestinal disorders, such as, gastroparesis, either idiopathic or associated with diabetic neuropathy, anorexia nervosa, after vagotomy or partial gastrectomy (the symptoms mainly consist of early satiety, anorexia, nausea and vomiting); symptoms of X-ray or endoscopy negative upper digestive discomfort, characterized by early satiety, postprandial fullness, inability to finish a normal sized meal, bloating, excessive belching, anorexia, nausea, vomiting or by ulcer-like complaints (epigastric burning or pain), gastro-esophageal reflux disorders, including the curative and maintenance treatment of oesophagitis; in babies: chronic and excessive regurgitation or vomiting, when positional and dietary measures have failed; intestinal pseudo-obstruction, associated with motility dysfunctions resulting in insufficient propulsive peristaltism and in stasis of gastric and intestinal contents;
  • the present invention further provides for a method of treating gastrointestinal disorders, especially gastro-oesophagal reflux disease. Due to the properties of the present tablets the use of cisapride-(L)-tartrate, cisapride - (D)-tartrate, cisapride sulfate, cisapride citrate for the manufacture of an oral dosage form without drugfood interaction for the treatment of gastrointestinal disorders is disclosed.
  • cisapride-(L)-tartrate cisapride-(D)-tartrate
  • cisapride sulfate cisapride citrate
  • cisapride citrate for the manufacture of a medicament for treating gastrointestinal disorders in patients taking medication that increases the pH of the stomach in general or for the manufacture of a medicament for treating gastrointestinal patients taking proton pump inhibitors, H2-inhibitors or antacids in particular is claimed.
  • this invention provides a therapeutic package suitable for commercial sale, comprising a container, an oral dosage form of cisapride which does not exhibit an adverse food effect contained therein and associated with said package, written (i.e. printed) matter non-limited as to whether the dosage form can be taken with or without food.
  • the written matter is of the type containing information and/or instructions for the physician, pharmacist or patient.
  • the written material can be "non-limited as to whether the dosage form can be taken with or without food" by virtue of including no statement regarding whether or not the dosage form can be taken with or without food, i.e. the statement is silent with regard to food effects.
  • the written material can be non-limited by containing one or more statements affirmatively informing the user (i.e. the patient, pharmacist, or physician) that the said oral dosage form can be taken by or administered to a patient regardless whether the patient has eaten or otherwise imbibed food (optionally, for example, also stating something like "without regard to the type or quantity of food”).
  • the written material cannot contain limiting language with respect to food, e.g., "This dosage form can not be taken with food” or "This dosage form may only be given after the patient has fasted” or the like.
  • the container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag, or a blister pack with individual dosages for pressing out of the pack according to a therapeutic schedule.
  • a pharmaceutically acceptable material for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag, or a blister pack with individual dosages for pressing out of the pack according to a therapeutic schedule.
  • the container employed can depend on the exact dosage form involved. - -
  • the dosage form can be administered "pro re nat ⁇ ".
  • the administration of the dosage form can be symptom driven.
  • the patient can take the present dosage form when the patient feels one of the symptoms which are associated with the gastrointestinal disorder he is suffering from. This greatly improves the patient compliance because instead of having to think about taking his medication at the meal, the patient can take in the medication when the symptoms appear.
  • Example 1 Tablet A
  • the tablet prepared according to the example above comprises : cisapride-(L)-tartrate 13.23 mg 7.35 % (w/w) MICROCELAC® 57.23 mg 87.35 % (w/w) croscarmellose sodium 7.2 mg 4.00 % (w/w) colloidal anhydrous silica 0.54 mg 0.3 % (w/w) magnesium stearate 1.8 mg 1.00 % (w/w)
  • Example 2 Tablet B The following ingredients were intimately mixed in a planetary mixer : cisapride-(L)- tartrate (13.23 mg, 7.35 % (w/w)), lactose DC (1 16.57 mg, 64.76 % (w/w)), micro- crystalline cellulose (Avicel®) (38.86 mg, 21.59 % (w/w)), croscarmellose sodium (7.2 mg, (4.00 % (w/w)), colloidal anhydrous silica (0.54 mg, 0.3 % (w/w)), sodium stearyl fumarate (3.6 mg, 2.00 % (w/w)) and compressed in a tabletting machine (type Korsch or Courtoy RO 2EHS, with compression rate of 36000 tabl/ h ) preparing tablets of 180 mg. - -
  • c isapri de- (L) -tartrate 13.23 mg 7.35 % (w/w) lactose DC 1 16.57 mg 64.76 % (w/w) microcrystalline cellulose 38.86 mg 21.59 % (w/w) croscarmellose sodium 7.2 mg 4.00 % (w/w) colloidal anhydrous silica 0.54 mg 0.3 % (w/w) sodium stearyl fumarate 3.6 mg 2.00 % (w/w)
  • Example 3 Tablet C In an analogous manner as described in Examples 1 and 2, tablets with the following composition were prepared :
  • cisapride-(L)-tartrate 6.61 mg 3.68 % (w/w) lactose 123.18 mg 68.44 % (w/w) microcrystalline cellulose 38.86 mg 21.59 % (w/w) croscarmellose sodium 7.2 mg 4.00 % (w/w) colloidal anhydrous silica 0.54 mg 0.3 % (w/w) magnesium stearate 1.8 mg 1.00 % (w/w)
  • cisapride-(L)-tartrate 26.44 mg 14.72 % (w/w) lactose 103.34 mg 58.39 % (w/w) microcrystalline cellulose 38.86 mg 21.59 % (w/w) croscarmellose sodium 7.2 mg 4.00 % (w/w) colloidal anhydrous silica 0.54 mg 0.30 % (w/w) magnesium stearate 1.8 mg 1.00 % (w/w)
  • Simethicone or alpha-D-galactosidase may be added to each of the above formulations to provide anti-flatulent relief.
  • the quantity of simethicone administered to a patient in need of treatment thereof may vary according to patient need, but may be, for example, the typical known dosage range to treat flatulence (20-40 mg per tablet) or may be increased as necessary.
  • the amount of ADG that may be employed in the above formulations ranges from about 675 to about 2250 GalU or may be increased as necessary.
  • Example 6 Preparation of film-coated tablets using the wet-granulation step for the tablet cores : Tablet F
  • the binder solution prepared as described under 6a) was sprayed unto the powder
  • the drying process started immediately after the spraying process. The drying process was continued until the outlet-air temperature reached about 38°C.
  • process parameters air flow rate : from about 400 to 1000 m /h, shaking time : 7 seconds, shaking time interval 35 seconds, temperature of the inlet air : from about 70 °C to about 75 °C, temperature of the outlet air : from about 37 °C to about 39
  • the dried granules prepared as described under 6b) were passed through an oscillating sieving apparatus of the type Frewitt (mesh openings : 1 mm, wire thickness : 0.65 mm) together with 2.772 kg of microcrystalline cellulose, 1.188 kg croscarmellose sodium, 1 18 g colloidal anhydrous silica and 198 g of magnesium stearate.
  • the sieved powder was collected in the bowl of the planetary mixer of the type Collette MP 90 (speed of mixing : mixing arm : 45 ⁇ m and the plateau : 20 ⁇ m) and was mixed during 5 minutes until a homogeneous mixture was obtained.
  • the compression mixture prepared as described under 6c) was pressed to tablets using a Killian rotary tablet press.
  • Biconvex, white circular tablets with a nominal weight of 180 mg were prepared in this way. These tablets were referred to as tablet core hereinabove.
  • mixture B 3.153 kg of purified water, 176 g talc, 264 g titanium dioxide and 33 g yellow ferric oxide were transferred in a stainless steel container of 10 1 and were homogenized for 10 to 15 minutes using a Silverson 2LR homogenizer. This mixture is referred to as mixture B.
  • Mixture B was added to mixture A while mixing with a propeller mixer(speed of mixing : from about 200 to about 400 ⁇ m). The total mixture was mixed during 120 minutes to further de-aerate the coating suspension.
  • the tablets were filled of in polyethylene bottles and Perlen tristar blisters.
  • Tablet core of tablet F is a
  • cisapride-(L)-tartrate 13.23 mg 7.35 % (w/w) lactose monohydrate 200 mesh(*l) 107.73 mg 59.85 % (w/w) unmodified maize starch 36.00 mg 20.00 % (w/w) HPMC 2910 15 mPa.s(*2) 3.60 mg 2.00 % (w/w) microcrystalline cellulose 12.60 mg 7.00 % (w/w) croscarmellose sodium 5.40 mg 3.00 % (w/w) colloidal anhydrous silica 0.54 mg 0.30 % (w/w) magnesium stearate 0.90 mg 0.50 % (w/w)
  • Titanium dioxide (E171 ) 1.20 mg 16.78 % (w/w)
  • HPMC means hydroxypropyl methylcellulose
  • the number "2910” refers to the type of hydroxypropyl methylcellulose that is used.
  • the first two digits,"29" represent the approximate percentage of methoxylgroups and the third and fourth digit," 10" represents the approximate percentage of hydroxypropylgroups.. - -
  • cisapride-(L)-tartrate 26.46 mg 12.03 % lactose monohydrate 200 mesh 1 1 1.48 mg 50.67 % unmodified maize starch 44.00 mg 20.00 % croscarmellose sodium (*) 4.95 mg 2.25 %
  • HPMC 2910 15 mPa.s 2.75 mg 1.25 % microcrystalline cellulose l l.OO mg 5.00 % croscarmellose sodium (*) 17.60 mg 8.00 % colloidal anhydrous silica 0.66 mg 0.30 % magnesium stearate l .lO mg 0.50 %
  • the tablet was coated as described under Example 6.
  • HPMC 2910 15 mPa.s 2.20 mg 1.00 % microcrystalline cellulose 4.40 mg 2.00 % croscarmellose sodium (*) 17.60 mg 8.00 % colloidal anhydrous silica 0.66 mg 0.30 % magnesium stearate l . lO mg 0.50 %
  • the tablet was coated as described under Example 6.
  • Example 9 Tablet I : tablet comprising equivalent of 5 mg cisapride base
  • HPMC 2910 15 mPa.s 2.00 mg 2.00 % microcrystalline cellulose 7.00 mg 7.00 % croscarmellose sodium 3.00 mg 3.00 % colloidal anhydrous silica 0.30 mg 0.30 % magnesium stearate 0.50 mg 0.50 %
  • Example 10 Tablet J : tablet comprising equivalent of 10 mg cisapride base
  • HPMC 2910 15 mPa.s 3.60 mg 2.00 % microcrystalline cellulose 12.60 mg 7.00 % croscarmellose sodium 5.40 mg 3.00 % colloidal anhydrous silica 0.54 mg 0.30 % magnesium stearate 0.90 mg 0.50 %
  • Example 1 1 Tablet K : tablet comprising equivalent of 20 mg of cisapride base
  • total weight of the tablet core 220.00 mg - -
  • the powder is filled off in a capsule type number 4
  • Example 13 Capsule B ingredient amount %(w/w) based on total weight of content
  • the powder is filled off in a capsule type number 2
  • the capsules as described above are prepared by mixing the ingredients in a planetary mixer and filling the powder of in the appropriate capsules.
  • test tablet was brought in a glass container containing 900 ml of the specified buffer at a temperature of 37 °C.
  • the stirring is performed by a paddle at a rotational speed of 50 ⁇ m (rotations per minute).
  • This test is s set forth in USP test ⁇ 71 1> in a USP-2 dissolution apparatus. This latter test is described in US Pharmacopeia XXII, pp 1578-1579.
  • Treatment A a single intake of a cisapride-(L)-tartrate tablet, 2 hours before a standard breakfast, i.e. fasting conditions.
  • Treatment B a single intake of a cisapride-(L)-tartrate tablet immediately after the standard breakfast.
  • Treatment C a single intake of cisapride monohydrate tablet (regular Prepulsid tablet),
  • Treatment D a single intake of cisapride monohydrate tablet (regular Prepulsid tablet), after the standard breakfast.
  • a standard breakfast consists of four slices of bread, one slice of ham, one slice of cheese, butter, jelly and two cups of coffee or tea with if desired milk and/or sugar, was served.
  • treatments B and D subjects first had their breakfast and took their trial medication immediately after finishing it. Thereafter, subjects could resume their usual diet.
  • the trial medication was taken with 100 ml water.
  • Plasma samples were taken until 48 h post-dosing.
  • the relative bioavailability of cisapride was calculated as the ratios of the Cmax and the AUC in the various treatments
  • Geometric mean Cmax ratios were 107 %, (B versus A), 80 % (C versus A), 133 % (D versus C) and 100 % (B versus D), with associated classical 90 %-confidence intervals of 98 %-l 16 %, 74-87 %. 122-145 % and 92-109%.
  • Geometric mean AUC ⁇ ratios were 114 %, (B versus A), 88% (C versus A), 129 % (D versus C) and 101 % (B versus D), with associated classical 90%-confidence intervals of 106-123 %, 81-94%, 120-139 % and 92-107%.
  • the regular marketed cisapride monohydrate is subject of a 30 % increased bioavailability in fed conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des formes galéniques, destinées à une administration orale, de certains sels de cisapride, notamment de cisapride-(L)-tartrate, cisapride-(D)-tartrate, cisapride-sulfate ou cisapride citrate, ces sels évitant qu'il y ait une interaction entre les médicaments et la nourriture et permettant une comédication d'agents augmentant le pH de l'estomac. Cette invention se rapporte notamment à des formes galéniques solides pour administration orale appropriées à une dissolution rapide, ainsi que des comprimés pouvant être préparés par compression directe.
PCT/EP1997/001462 1996-04-23 1997-03-20 Forme galenique solide de cisapride independante du ph a liberation immediate WO1997039744A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ331705A NZ331705A (en) 1996-04-23 1997-03-20 Immediate release ph-independent solid dosage form of cisapride
JP9537646A JPH10510559A (ja) 1996-04-23 1997-03-20 シサプリドの即時放出性ｐＨ非依存性固形製剤
SK1446-98A SK144698A3 (en) 1996-04-23 1997-03-20 Immediate release ph-independent solid dosage form of cisapride
EA199800861A EA000804B1 (ru) 1996-04-23 1997-03-20 Твердая лекарственная форма, содержащая производные цизаприда, способ ее получения, продукт, содержащий твердую лекарственную форму, фармацевтическая упаковка
EE9800269A EE03552B1 (et) 1996-04-23 1997-03-20 Tahke doseerimisvorm, selle valmistamismeetod, seda sisaldav produkt, tablett ja farmatseutiline pakend ning tsisapriidisoolade kasutamine
AU22904/97A AU720582B2 (en) 1996-04-23 1997-03-20 Immediate release PH-independent solid dosage form of cisapride
BR9708585A BR9708585A (pt) 1996-04-23 1997-03-20 Forma de dosagem sólida Ph-independente de liberação imediata da cisaprida
PL97328917A PL328917A1 (en) 1996-04-23 1997-03-20 Solid administration ph-independent administration form of directly released cisapride
IL12597997A IL125979A0 (en) 1996-04-23 1997-03-20 Immediate release ph-independent solid dosage form of cisapride
NO984016A NO984016L (no) 1996-04-23 1998-09-01 Ïyeblikkelig frigivelses pH-avhengig fast doseringsform av cisaprid
BG102812A BG102812A (en) 1996-04-23 1998-10-01 SOLID DOSED OUT FORM OF CISAPRID HAVING IMMEDIATE RELEASE INDEPENDENT OF pH

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201078 1996-04-23
EP96201078.1 1996-04-23

Publications (1)

Publication Number Publication Date
WO1997039744A1 true WO1997039744A1 (fr) 1997-10-30

Family

ID=8223900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/001462 WO1997039744A1 (fr) 1996-04-23 1997-03-20 Forme galenique solide de cisapride independante du ph a liberation immediate

Country Status (23)

Country Link
US (1) US6030988A (fr)
JP (1) JPH10510559A (fr)
KR (1) KR100204115B1 (fr)
CN (1) CN1216467A (fr)
AR (1) AR006790A1 (fr)
AT (1) ATE220543T1 (fr)
AU (1) AU720582B2 (fr)
BG (1) BG102812A (fr)
BR (1) BR9708585A (fr)
CA (1) CA2201264C (fr)
CZ (1) CZ332598A3 (fr)
DE (1) DE69713948D1 (fr)
EA (1) EA000804B1 (fr)
EE (1) EE03552B1 (fr)
ID (1) ID16666A (fr)
IL (1) IL125979A0 (fr)
NO (1) NO984016L (fr)
NZ (1) NZ331705A (fr)
PL (1) PL328917A1 (fr)
SK (1) SK144698A3 (fr)
TR (1) TR199802139T2 (fr)
WO (1) WO1997039744A1 (fr)
ZA (1) ZA973449B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (fr) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Formulation solide a liberation prolongee/controlee en tant que nouveau systeme d'administration de medicaments a risque reduit de liberation massive
US7148207B2 (en) 2001-12-20 2006-12-12 Schering Aktiengesellschaft Oral fludara of high-purity formulation with quick release of active ingredient
CZ299105B6 (cs) * 2000-01-26 2008-04-23 Astrazeneca Ab Farmaceutická kompozice a použití povlaku obsahujícího oxid železitý

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20030138485A1 (en) * 1998-01-14 2003-07-24 Daiichi Pharmaceutical Co., Ltd. Disintegrant
ES2373864T3 (es) * 1998-04-20 2012-02-09 Eisai R&D Management Co., Ltd. Composición estabilizada que contiene un compuesto de tipo bencimidazol.
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US7220762B1 (en) 1999-10-20 2007-05-22 Eisai R&D Management Co., Ltd. Methods for stabilizing benzimidazole compounds
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
EP1321142A1 (fr) * 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
GB2390541A (en) * 2002-07-12 2004-01-14 Reckitt Benckiser Healthcare Medicinal composition comprising fibre or saccharide bulking agents
WO2004019937A1 (fr) * 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Composition pharmaceutique de metaxalone a biodisponibilite orale amelioree
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
TWI337877B (en) * 2003-07-18 2011-03-01 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CA2554271A1 (fr) * 2004-02-10 2005-08-25 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un tampon et d'un medicament anti-inflammatoire non steroidien
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
CA2609192A1 (fr) 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Formes posologiques orales contenant du progesterone et procedes de fabrication et d'utilisation desdites formes posologiques
CN1935264B (zh) * 2005-09-23 2010-05-05 北京德众万全医药科技有限公司 一种用于缓控释片的含有hpmc的新型复合辅料
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CN104352465B (zh) * 2014-11-17 2017-04-12 成都新恒创药业有限公司 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法
CN109394711A (zh) * 2018-11-06 2019-03-01 威海贯标信息科技有限公司 一种酒石酸西尼必利片组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001111A1 (fr) * 1992-07-07 1994-01-20 Sepracor Inc. Procedes d'utilisation de cisapride (+) pour le traitement du reflux gastro-×sophagien et d'autres troubles
WO1994001112A1 (fr) * 1992-07-07 1994-01-20 Sepracor Inc. Procedes d'utilisation de cisapride (-) pour le traitement du reflux gastro-×sophagien et d'autres troubles
WO1995001803A1 (fr) * 1993-07-06 1995-01-19 Merck & Co., Inc. Combinaisons d'agents anti-h2 et d'agents de motilite gastro-intestinale
EP0670160A1 (fr) * 1994-03-01 1995-09-06 Gerhard Dr. Gergely Produit granulaire ou comprimé contenant un système effervescent et un agent actif pharmaceutique, et son procédé de préparation
WO1995034284A1 (fr) * 1994-06-15 1995-12-21 Gerhard Gergely Preparation pharmaceutique comportant un principe actif hydrophobe et un systeme effervescent, et procede de fabrication de ladite preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001111A1 (fr) * 1992-07-07 1994-01-20 Sepracor Inc. Procedes d'utilisation de cisapride (+) pour le traitement du reflux gastro-×sophagien et d'autres troubles
WO1994001112A1 (fr) * 1992-07-07 1994-01-20 Sepracor Inc. Procedes d'utilisation de cisapride (-) pour le traitement du reflux gastro-×sophagien et d'autres troubles
WO1995001803A1 (fr) * 1993-07-06 1995-01-19 Merck & Co., Inc. Combinaisons d'agents anti-h2 et d'agents de motilite gastro-intestinale
EP0670160A1 (fr) * 1994-03-01 1995-09-06 Gerhard Dr. Gergely Produit granulaire ou comprimé contenant un système effervescent et un agent actif pharmaceutique, et son procédé de préparation
WO1995034284A1 (fr) * 1994-06-15 1995-12-21 Gerhard Gergely Preparation pharmaceutique comportant un principe actif hydrophobe et un systeme effervescent, et procede de fabrication de ladite preparation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299105B6 (cs) * 2000-01-26 2008-04-23 Astrazeneca Ab Farmaceutická kompozice a použití povlaku obsahujícího oxid železitý
US7148207B2 (en) 2001-12-20 2006-12-12 Schering Aktiengesellschaft Oral fludara of high-purity formulation with quick release of active ingredient
WO2003074033A1 (fr) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Formulation solide a liberation prolongee/controlee en tant que nouveau systeme d'administration de medicaments a risque reduit de liberation massive

Also Published As

Publication number Publication date
CZ332598A3 (cs) 1999-01-13
EA199800861A1 (ru) 1999-02-25
KR100204115B1 (ko) 1999-06-15
ATE220543T1 (de) 2002-08-15
ZA973449B (en) 1998-10-22
JPH10510559A (ja) 1998-10-13
SK144698A3 (en) 1999-05-07
BR9708585A (pt) 1999-08-03
DE69713948D1 (de) 2002-08-22
CN1216467A (zh) 1999-05-12
KR970069038A (ko) 1997-11-07
AU720582B2 (en) 2000-06-08
NO984016D0 (no) 1998-09-01
PL328917A1 (en) 1999-03-01
CA2201264A1 (fr) 1997-10-23
AR006790A1 (es) 1999-09-29
US6030988A (en) 2000-02-29
EE03552B1 (et) 2001-12-17
EA000804B1 (ru) 2000-04-24
TR199802139T2 (xx) 1999-03-22
CA2201264C (fr) 1999-08-10
NO984016L (no) 1998-12-23
AU2290497A (en) 1997-11-12
ID16666A (id) 1997-10-30
IL125979A0 (en) 1999-04-11
EE9800269A (et) 1999-02-15
NZ331705A (en) 1999-11-29
BG102812A (en) 1999-05-31

Similar Documents

Publication Publication Date Title
US6030988A (en) Immediate release pH-independent solid dosage form of cisapride
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
JP5854476B2 (ja) 圧縮性コーティングで被覆された医薬組成物及び錠剤並びに製造方法
EP0922464B1 (fr) Materiaux moules par compression, a desagregation rapide, et leur procede de production
KR101965002B1 (ko) 급속 분산성 과립, 구강 붕해성 정제 및 방법
EP1638529B1 (fr) Composition orale a liberation prolongee
KR100536783B1 (ko) 급속 붕해성 고체 제제
TW460282B (en) Antifungal compositions with improved bioavailability
US9492541B2 (en) Phenylepherine containing dosage form
AU2012357956A1 (en) Immediate release multi unit pellet system
WO2019130749A1 (fr) Nouveau revêtement de microparticules (particules creuses comprenant un médicament et procédé de fabrication de celles-ci)
KR100846945B1 (ko) 파라세타몰을 포함하는 연하 정제
ZA200308664B (en) Solid orally-dispersible pharmaceutical formulation.
EP4281047A1 (fr) Compositions pharmaceutiques de dasatinib à dissolution rapide
EP0803251B1 (fr) Formes solides d'administration de cisapride à libération immédiate et indépendente du PH
JP5138856B2 (ja) 錠剤の製造方法
WO1998056364A1 (fr) Forme galenique solide a liberation immediate independante du ph de (+)- ou (-)-cisapride
CN108289849A (zh) 莫沙必利与雷贝拉唑的复合制剂
US8653135B1 (en) Alternating sympathomimetic therapy for the treatment of respiratory aliments
MXPA98008710A (en) Dosage form solid independent of the ph, of immediate release
WO2024053680A1 (fr) Comprimé orodispersible
EP2558079B1 (fr) Composition sèche de ciprofloxacine pour suspension buvable
EP3251661A1 (fr) Composition de saupoudrage de raloxifène
CN112839636A (zh) 包衣方法
WO2014027974A1 (fr) Formulation de palipéridone à désintégration orale

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97193987.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BA BB BG BR CN CU CZ EE GE HU IL IS JP LC LK LR MG MK MN MX NO NZ PL SG SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 331705

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1998-3325

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 144698

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/008710

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998/02139

Country of ref document: TR

Ref document number: 199800861

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: PV1998-3325

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1998-3325

Country of ref document: CZ